Xencor Inc stock (US98401F1057): shares react to Monjuvi first-line lymphoma update and recent Q1 2026 loss

Xencor Inc shares on Nasdaq are trading against the backdrop of a wider immunotherapy spotlight after partner Incyte flagged Monjuvi as a potential first-line lymphoma treatment on 05/30/2026, while investors continue to digest the US biotech group’s Q1 2026 loss reported earlier in May.

Xencor Inc shares on the Nasdaq Global Market are trading in focus for US biotech investors after partner Incyte highlighted on 05/30/2026 that their jointly developed immunotherapy Monjuvi could become a first-line treatment option for certain lymphoma patients, while the United States-based company is still being assessed in light of its Q1 2026 loss reported on 05/06/2026, when it posted earnings per share of USD -1.71 compared with a consensus forecast of USD -0.75, according to data compiled by MarketBeat as of that date.

The stock remains listed in the United States under ticker XNCR on Nasdaq, giving it exposure to key US indices watched by biotech specialists, and the latest combination of clinical news flow and quarterly numbers provides a fresh fundamental backdrop for traders in both New York and European off-exchange venues such as Tradegate where the shares are also accessible in euro terms.

As of: 01/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: XNCR
• Sector/industry: Biotechnology, antibody and protein engineering
• Headquarters/country: Pasadena, United States
• Core markets: United States and global biopharmaceutical partners
• Key revenue drivers: Royalties, milestones and collaboration revenues from engineered antibody and cytokine programs
• Home exchange/listing venue: Nasdaq Global Market (XNCR)
• Trading currency: USD

Xencor Inc: core business model

Xencor focuses on designing and licensing engineered antibodies and cytokine therapies to large pharmaceutical partners, who in turn drive revenue potential through milestone payments, royalties and co-development economics on successfully commercialized medicines.

What banks and research houses say about Xencor Inc

No verified analyst coverage was identified at the time of publication.

Conclusion

The latest move by US partner Incyte to position Monjuvi, which uses Xencor’s antibody engineering technology, as a potential first-line lymphoma therapy places fresh attention on the company’s collaboration-driven pipeline and royalty model.

At the same time, the Q1 2026 net loss and earnings per share of USD -1.71 reported on 05/06/2026 against a consensus of USD -0.75 underline that the Nasdaq-listed biotech name remains in an investment phase where clinical and partnering milestones can matter as much as near-term profitability when investors evaluate the shares.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.